Browsing Tag
IRAK1/4 inhibitor
1 post
Rigel Pharmaceuticals’ R289 delivers promising phase 1b results in transfusion-dependent MDS
Find out how Rigel Pharmaceuticals, Inc. is advancing R289 for lower-risk myelodysplastic syndrome with promising new phase 1b data—read the latest insights now!